These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32981222)

  • 21. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
    Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
    J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic therapy in erythrodermic and pustular psoriasis.
    Levin EC; Debbaneh M; Koo J; Liao W
    J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
    Gottlieb AB; Gordon K; Hsu S; Elewski B; Eichenfield LF; Kircik L; Rastogi S; Pillai R; Israel R
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
    N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brodalumab versus ustekinumab in psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
    Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
    Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials.
    Hsu S; Green LJ; Lebwohl MG; Wu JJ; Blauvelt A; Jacobson AA
    Br J Dermatol; 2020 Apr; 182(4):880-888. PubMed ID: 31276189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.
    Saraceno R; Talamonti M; Galluzzo M; Chiricozzi A; Costanzo A; Chimenti S
    Case Rep Dermatol; 2013; 5(3):254-9. PubMed ID: 24163658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.
    Xu G; Xia M; Jiang C; Yu Y; Wang G; Yuan J; Duan X
    J Pharmacol Sci; 2019 Apr; 139(4):289-303. PubMed ID: 30922656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
    Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
    [No Abstract]   [Full Text] [Related]  

  • 32. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.
    Hu Y; Chen Z; Gong Y; Shi Y
    Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
    Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G
    Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological therapy for pustular psoriasis: a systematic review.
    Falto-Aizpurua LA; Martin-Garcia RF; Carrasquillo OY; Nevares-Pomales OW; Sánchez-Flores X; Lorenzo-Rios D
    Int J Dermatol; 2020 Mar; 59(3):284-296. PubMed ID: 31612467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological treatment for erythrodermic psoriasis.
    Dogra S; Mehta H
    Expert Opin Biol Ther; 2022 Dec; 22(12):1531-1543. PubMed ID: 36154361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
    Salinger DH; Endres CJ; Martin DA; Gibbs MA
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Mieno M; Ohtsuki M
    J Dermatol; 2020 Jan; 47(1):33-40. PubMed ID: 31696543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.